Impact of pretransplant minimal residual disease after cord blood transplantation for childhood acute lymphoblastic leukemia in remission: an Eurocord, PDWP

Impact of pretransplant minimal residual disease after cord blood transplantation for childhood acute lymphoblastic leukemia in remission: an Eurocord, PDWP–EBMT analysis

Published:2012-05-04 Issue:12 Volume:26 Page:2455-2461
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Ruggeri A,Michel G,Dalle J-H,Caniglia M,Locatelli F,Campos A,de Heredia C D,Mohty M,Hurtado J M P,Bierings M,Bittencourt H,Mauad M,Purtill D,Cunha R,Kabbara N,Gluckman E,Labopin M,Peters C,Rocha V

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu2012123.pdf

Reference44 articles.

1. Schrappe M, Reiter A, Zimmermann M, Harbott J, Ludwig WD, Henze G et al. Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Munster. Leukemia 2000; 14: 2205–2222.

2. Pui CH, Evans WE . Acute lymphoblastic leukemia. N Engl J Med 1998; 339: 605–615.

3. Conter V, Arico M, Basso G, Biondi A, Barisone E, Messina C et al. Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) Studies 82, 87, 88, 91 and 95 for childhood acute lymphoblastic leukemia. Leukemia 2010; 24: 255–264.

4. Leung W, Campana D, Yang J, Pei D, Coustan-Smith E, Gan K et al. High success rate of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemia. Blood 2011; 118: 223–230.

5. Rocha V, Locatelli F . Searching for alternative hematopoietic stem cell donors for pediatric patients. Bone Marrow Transplant 2008; 41: 207–214.

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Engineering the best transplant outcome for high-risk acute myeloid leukemia: the donor, the graft and beyond;Cytotherapy;2023-12

2. A predictive model combining clinical characteristics and nutritional risk factors for overall survival after umbilical cord blood transplantation;Stem Cell Research & Therapy;2023-10-23

3. Efficacy and safety of blinatumomab in children with relapsed/refractory B cell acute lymphoblastic leukemia: A systematic review and meta-analysis;Frontiers in Pharmacology;2023-01-10

4. Blinatumomab overcomes poor prognostic impact of measurable residual disease in pediatric high‐risk first relapse B‐cell precursor acute lymphoblastic leukemia;Pediatric Blood & Cancer;2022-04-28

5. Blinatumomab in pediatric relapsed/refractory B-cell acute lymphoblastic leukemia: RIALTO expanded access study final analysis;Blood Advances;2022-02-04